FR2909286B1 - Methode d'immunisation contre les 4 serotypes de la dengue - Google Patents

Methode d'immunisation contre les 4 serotypes de la dengue

Info

Publication number
FR2909286B1
FR2909286B1 FR0655255A FR0655255A FR2909286B1 FR 2909286 B1 FR2909286 B1 FR 2909286B1 FR 0655255 A FR0655255 A FR 0655255A FR 0655255 A FR0655255 A FR 0655255A FR 2909286 B1 FR2909286 B1 FR 2909286B1
Authority
FR
France
Prior art keywords
serotypes
dengue
immunization method
method against
immunization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0655255A
Other languages
English (en)
French (fr)
Other versions
FR2909286A1 (fr
Inventor
Bruno Guy
Veronique Barban
Remi Forrat
Jean Lang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Inc
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Priority to FR0655255A priority Critical patent/FR2909286B1/fr
Priority to TW096143113A priority patent/TWI400249B/zh
Priority to US11/944,311 priority patent/US7718359B2/en
Priority to ARP070105280A priority patent/AR064009A1/es
Priority to JP2009538758A priority patent/JP5269803B2/ja
Priority to CNA2007800439553A priority patent/CN101541344A/zh
Priority to MX2009004223A priority patent/MX2009004223A/es
Priority to AU2007327367A priority patent/AU2007327367B2/en
Priority to ZA200902540A priority patent/ZA200902540B/xx
Priority to EP07866551.0A priority patent/EP2099483B1/fr
Priority to PCT/FR2007/052431 priority patent/WO2008065315A1/fr
Priority to BRPI0718927-3A2A priority patent/BRPI0718927A2/pt
Priority to MYPI20091957A priority patent/MY180698A/en
Priority to KR1020097010676A priority patent/KR20090087890A/ko
Priority to CA002668570A priority patent/CA2668570A1/en
Publication of FR2909286A1 publication Critical patent/FR2909286A1/fr
Priority to IL198466A priority patent/IL198466A/en
Priority to US12/718,931 priority patent/US20100239612A1/en
Application granted granted Critical
Publication of FR2909286B1 publication Critical patent/FR2909286B1/fr
Priority to IL230052A priority patent/IL230052A0/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR0655255A 2006-12-01 2006-12-01 Methode d'immunisation contre les 4 serotypes de la dengue Expired - Fee Related FR2909286B1 (fr)

Priority Applications (18)

Application Number Priority Date Filing Date Title
FR0655255A FR2909286B1 (fr) 2006-12-01 2006-12-01 Methode d'immunisation contre les 4 serotypes de la dengue
TW096143113A TWI400249B (zh) 2006-12-01 2007-11-14 針對４個登革熱血清型的免疫方法
US11/944,311 US7718359B2 (en) 2006-12-01 2007-11-21 Method of immunization against the 4 serotypes of dengue fever
ARP070105280A AR064009A1 (es) 2006-12-01 2007-11-28 Metodo de inmunizacion contra los 4 serotipos del dengue
KR1020097010676A KR20090087890A (ko) 2006-12-01 2007-11-30 4 가지 뎅기열 혈청형에 대한 면역화 프로토콜
MX2009004223A MX2009004223A (es) 2006-12-01 2007-11-30 Protocolo de inmunizacion contra los 4 serotipos del dengue.
AU2007327367A AU2007327367B2 (en) 2006-12-01 2007-11-30 Immunization protocol against the 4 dengue serotypes
ZA200902540A ZA200902540B (en) 2006-12-01 2007-11-30 Immunization protocol against the 4 dengue serotypes
EP07866551.0A EP2099483B1 (fr) 2006-12-01 2007-11-30 Methode d'immunisation contre les 4 serotypes de la dengue
PCT/FR2007/052431 WO2008065315A1 (fr) 2006-12-01 2007-11-30 Methode d'immunisation contre les 4 serotypes de la dengue
JP2009538758A JP5269803B2 (ja) 2006-12-01 2007-11-30 デング熱の４種の血清型に対する免疫付与のプロトコル
MYPI20091957A MY180698A (en) 2006-12-01 2007-11-30 Immunization protocol against the 4 dengue serotypes
CNA2007800439553A CN101541344A (zh) 2006-12-01 2007-11-30 针对4种登革热血清型的免疫方法
CA002668570A CA2668570A1 (en) 2006-12-01 2007-11-30 Immunization protocol against the 4 dengue serotypes
BRPI0718927-3A2A BRPI0718927A2 (pt) 2006-12-01 2007-11-30 Método de imunização contra os quatro sorotipos da dengue.
IL198466A IL198466A (en) 2006-12-01 2009-04-30 Use of dengue fever vaccines to produce a single-value vaccine and four-value vaccine to vaccinate against dengue fever virus and vaccine kits against dengue fever containing these vaccines
US12/718,931 US20100239612A1 (en) 2006-12-01 2010-03-05 Method of Immunization Against the 4 Serotypes of Dengue Fever
IL230052A IL230052A0 (en) 2006-12-01 2013-12-19 A method for vaccination against 4 serotypes of dengue

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0655255A FR2909286B1 (fr) 2006-12-01 2006-12-01 Methode d'immunisation contre les 4 serotypes de la dengue

Publications (2)

Publication Number Publication Date
FR2909286A1 FR2909286A1 (fr) 2008-06-06
FR2909286B1 true FR2909286B1 (fr) 2012-06-08

Family

ID=38198298

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0655255A Expired - Fee Related FR2909286B1 (fr) 2006-12-01 2006-12-01 Methode d'immunisation contre les 4 serotypes de la dengue

Country Status (16)

Country Link
US (2) US7718359B2 (enExample)
EP (1) EP2099483B1 (enExample)
JP (1) JP5269803B2 (enExample)
KR (1) KR20090087890A (enExample)
CN (1) CN101541344A (enExample)
AR (1) AR064009A1 (enExample)
AU (1) AU2007327367B2 (enExample)
BR (1) BRPI0718927A2 (enExample)
CA (1) CA2668570A1 (enExample)
FR (1) FR2909286B1 (enExample)
IL (2) IL198466A (enExample)
MX (1) MX2009004223A (enExample)
MY (1) MY180698A (enExample)
TW (1) TWI400249B (enExample)
WO (1) WO2008065315A1 (enExample)
ZA (1) ZA200902540B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1924280A4 (en) * 2005-08-10 2008-12-10 Acambis Inc VACCINATION AGAINST DENGUE VIRUS INFECTION
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
MX2010008799A (es) 2008-03-05 2010-09-07 Sanofi Pasteur Proceso para estabilizar una composicion de vacuna que contiene adyuvante.
EP2143440A1 (fr) * 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
CN102449172A (zh) * 2009-06-01 2012-05-09 伊维拉根公司 施用针对登革病毒的疫苗的组合物和方法
CA2770888C (en) * 2009-08-31 2020-04-14 Gen-Probe Incorporated Dengue virus assay
EP2353609A1 (en) * 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
WO2012088041A1 (en) 2010-12-20 2012-06-28 Genvec, Inc. Adenoviral vector-based dengue fever vaccine
MY168959A (en) 2012-07-24 2019-01-28 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection
WO2014016362A1 (en) 2012-07-24 2014-01-30 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
US9861692B2 (en) * 2013-06-21 2018-01-09 Merck Sharp & Dohme Corp. Dengue virus vaccine compositions and methods of use thereof
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
EP3316905A1 (en) 2015-07-03 2018-05-09 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
US10004795B2 (en) 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine
JP7313345B2 (ja) 2017-10-05 2023-07-24 サノフィ・パスツール デング熱に対するブースターワクチン接種のための組成物
ES2908304T3 (es) 2018-09-05 2022-04-28 Takeda Vaccines Inc Dosis unitaria de vacuna contra el dengue y administración de la misma
PH12022550261A1 (en) 2019-08-16 2023-06-26 Takeda Vaccines Inc Methods for preventing dengue and hepatitis a
WO2021174059A1 (en) 2020-02-27 2021-09-02 Takeda Vaccines, Inc. Method for removing host cell dna from virus preparation
WO2023147337A2 (en) 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
US20250177511A1 (en) 2022-02-15 2025-06-05 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
WO2023215383A1 (en) 2022-05-04 2023-11-09 Takeda Vaccines, Inc. Computer-based determination of flavivirus infectivity
EP4375381A1 (en) 2022-11-18 2024-05-29 Takeda Vaccines, Inc. A method for determining the proportion of a live, attenuated flavivirus having a nucleotide sequence comprising at least one attenuation locus in a formulation
EP4626574A1 (en) 2022-11-29 2025-10-08 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2025072259A1 (en) 2023-09-25 2025-04-03 Takeda Vaccines, Inc. Coadministration of tetravalent dengue vaccine with hpv vaccine
WO2025122855A1 (en) 2023-12-08 2025-06-12 Takeda Vaccines, Inc. A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2332786A1 (en) 1998-05-29 1999-12-02 Epimmune Inc. Identification of broadly reactive dr restricted epitopes
DE60041250D1 (de) * 1999-03-26 2009-02-12 Us Army Multivalenter dengue-virus impfstoff
AU4040400A (en) 1999-03-26 2000-10-16 Walter Reed Army Institute Of Research Attenuated dengue-4 virus vaccine
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
WO2001060847A2 (en) * 2000-02-16 2001-08-23 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Avirulent, immunogenic flavivirus chimeras
EP1159969A1 (fr) 2000-05-30 2001-12-05 Aventis Pasteur Vaccine composition
ATE412738T1 (de) * 2000-05-30 2008-11-15 Univ Mahidol Attenuierte stammen von denguevirus und ihre verwendungen in impfstoffzusammensetzungen
AU2003239932A1 (en) * 2002-05-31 2003-12-19 Acambis, Inc. Tetravalent dengue vaccines
CA2519953C (en) * 2003-03-24 2016-01-05 The Scripps Research Institute Dna vaccine against tumor growth and methods of use thereof
MX2007015872A (es) * 2005-06-17 2008-04-21 Sanofi Pasteur Cepa atenuada del serotipo 2 del dengue.
CA2611934C (en) * 2005-06-17 2015-11-03 Sanofi Pasteur Dengue serotype 1 attenuated strain
EP1924280A4 (en) * 2005-08-10 2008-12-10 Acambis Inc VACCINATION AGAINST DENGUE VIRUS INFECTION
US7968102B2 (en) * 2006-01-13 2011-06-28 Sanofi Pasteur S.A. Dengue chimeric viruses
AR061197A1 (es) * 2006-06-07 2008-08-13 Sanofi Pasteur Cepas del virus 3 del dengue vivas atenuadas
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.

Also Published As

Publication number Publication date
IL198466A0 (en) 2011-08-01
AU2007327367A1 (en) 2008-06-05
WO2008065315A1 (fr) 2008-06-05
CN101541344A (zh) 2009-09-23
US7718359B2 (en) 2010-05-18
MX2009004223A (es) 2009-04-30
TW200829599A (en) 2008-07-16
AU2007327367B2 (en) 2013-05-09
BRPI0718927A2 (pt) 2014-04-08
KR20090087890A (ko) 2009-08-18
EP2099483A1 (fr) 2009-09-16
JP2010511022A (ja) 2010-04-08
ZA200902540B (en) 2010-07-28
IL198466A (en) 2014-01-30
CA2668570A1 (en) 2008-06-05
JP5269803B2 (ja) 2013-08-21
TWI400249B (zh) 2013-07-01
MY180698A (en) 2020-12-07
FR2909286A1 (fr) 2008-06-06
AR064009A1 (es) 2009-03-04
EP2099483B1 (fr) 2013-12-25
US20080131460A1 (en) 2008-06-05
IL230052A0 (en) 2014-01-30
US20100239612A1 (en) 2010-09-23

Similar Documents

Publication Publication Date Title
FR2906724B1 (fr) Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) Methode d'immunisation contre les 4 serotypes de la dengue
ZA200900155B (en) Method of immunisation against the four serotypes of dengue
EP2318530A4 (en) NEW EPITOP FOR IMMUNIZING AGAINST INFLUENZA VIRUS
LT2351578T (lt) Vakcinų gavimo būdas
BRPI0810270A2 (pt) "implante de válvula cardíaca e método de implante"
EP2076221A4 (en) IMPLANT FOR ARTHRODESIS
DK2077287T3 (da) Fremgangsmåde til fremstilling af blødt polyurethanskum
EP1888765A4 (en) METHOD AND COMPOSITIONS FOR DIAGNOSIS OF VENOUS THROMBOEMBOLIC ILLNESSES
EP2037738A4 (en) feeding method
EP2083845A4 (en) ABLATIVE IMMUNOTHERAPY
NO20050773D0 (no) Umbilical og fremgangsmate for dens fremstilling
GB0910201D0 (en) The preparation method of 2-deoxy-l-ribose
EP2305292A4 (en) TRANSDERMAL IMMUNIZER OF S / O TYPE
GB0605247D0 (en) Compositions and methods for immunisation
EP2061506A4 (en) VACCINE COMPOSITION AND IMMUNIZATION PROCEDURE
NO20064595A (no) Titanimplantat og fremgangsmåte for fremstilling derav
ITMI20061848A1 (it) Procedimento per la preparazione di composti feniltetrazolici
PL1853220T5 (pl) Sposób wytwarzania pastylek zawierających NLPZ, ich kompozycje, ich zastosowanie medyczne
EP1904097A4 (en) MALARIA MSP-1 C-TERMINAL REINFORCED SUBUNIT VACCINE
ITMI20060489A1 (it) Procedimento per la preparazione di 1-beono-3-trifluorometossibenzene
ITMI20051910A1 (it) Metodo per la preparazione di colture batteriche probiotiche anallergiche e relativo impiego
ITMI20061212A1 (it) Metodo per la preparazione di colture batteriche probiotiche anallergiche e relativo impiego
ITMI20062515A1 (it) Procedimento per la preparazione di 3,6-di-o-aceti-d-glicali
ITPD20060075A1 (it) Metodo per la preparazione di rivestimenti del tipo mattone-a-vista e rivestimento cosi' ottenuto

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20160831